Artificial intelligence (AI) software developer Imbio and biotechnology firm Genentech have formed a partnership to develop quantitative imaging AI technology for diagnosing lung diseases.
The multiyear collaboration, which will bring together Imbio's experience with imaging biomarkers and Genentech's pulmonary disease knowledge, will seek to create and deploy medical imaging AI algorithms for use in research, clinical trials, and clinical practice, according to the vendors. The goal is to enhance drug development and enable more personalized healthcare, the firms said.
Imbio noted that it will also continue to develop and market its own portfolio of quantitative imaging algorithms for lung and cardiothoracic diseases outside of the partnership.
